- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Apogee Technology, Inc. (AMEX: ATA), an emerging micro-systems and nanotechnology company that designs, develops and commercializes medical devices and sensor products, reported today that Dr. R. Rox Anderson has agreed to join the Company's Medical Advisory Board. Dr. Anderson practices dermatology at Massachusetts General Hospital and is the Director of the Wellman Center for Photomedicine at Massachusetts General Hospital. In addition, Dr. Anderson is a Professor of Dermatology at Harvard Medical School and is an affiliated faculty member at the Massachusetts Institute of Technology (MIT).
Herbert Stein, Apogee's Chairman and Chief Executive Officer, said, "We are extremely excited to have a leading dermatologist supporting the development of our PyraDerm™ intradermal drug delivery platform. His expertise in the structure of the skin, the treatment of skin diseases and his medical technology development experience will be invaluable as we work towards the commercialization of our delivery solutions for FDA regulated and non regulated applications."
Dr. Anderson has conceived and developed dermatologic surgery using selectively absorbed laser pulses, which is now the preferred basis for treatment of birthmarks, pigmented lesions, tattoos, hypertrichosis and other conditions. He has made many contributions to the understanding and development of laser-tissue interactions, tissue optics, photodynamic therapy, and optical diagnostics. Dr. Anderson received his undergraduate degree from MIT and his M.D. from Harvard Medical School.
About Apogee Technology, Inc.
Apogee Technology designs, develops and commercializes proprietary medical device and sensor products using its MEMS and nanotechnology for the medical, automotive, industrial and consumer markets. The Company is developing its PyraDerm™ solution for enhanced intradermal drug delivery and has introduced a family of pressure sensors under the Sensilica® brand. Apogee's goal is to provide value-added and cost-saving solutions for our customers and, in so doing, become a global leader in the sensor and medical device fields. For more information please visit our web site at: http://www.apogeemems.com .
PyraDerm™ and Sensilica® are trademarks of Apogee Technology, Inc. All other product names noted herein may be trademarks of their respective holders. Certain statements made herein that use the words "anticipate," "hope," "estimate," "project," "will," "intend," "plan," "expect," "believe" and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties, which could cause the actual results, performance or achievements of the Company to be materially different from those that may be expressed or implied. Please refer to the company's risk factors as set forth in the Company's filings with the Securities and Exchange Commission, including its reports on Forms 10-KSB and 10-QSB.
For more information, please click here
Premier Funding & Financial Marketing
Copyright © Market WireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Electrically Conductive Graphene Ink Enables Printing of Biosensors April 23rd, 2016
Highlights from the Graphene Flagship April 22nd, 2016